The role of biological oncomarkers in the differential diagnosis of complex kidney cysts
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The renal cell carcinoma (RCC) ranks first place in mortality among urogenital tumors, and the incidence is third after prostate and bladder cancer. The cystic form of renal cell carcinoma is 5–7%, and according to recent data – even 10% of all kidney tumors. The early diagnosis of RCC allows for effective treatment, which significantly increases survival.
Early and accurate diagnosis helps to avoid inadequate treatment, provides a favorable prognosis for progression of the disease and allows for more effective therapy. Most of the renal tumors, including cystic, are diagnosed accidentally during an examination for other reasons. Small tumors are usually asymptomatic, which leads to late diagnosis, and consequently, to the low effectiveness of treatment.
Thus, the need for the use of sensitive biomarkers for early diagnosis of RCC and monitoring of its progression is clearly followed. Nowadays, many attempts have been made by scientists to identify a new informative kidney tumor biomarker that could be used for early diagnosis and disease progression, as well as prognostic capabilities. This overview summarizes the latest advances in the discovery of these biomarkers and their clinical value.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Eble J.N. Tumors of the Kidney/ N.J. Eble, G. Sauter, J.I. Epstein, I.A. Sesterhenn // Tumors of the urinary system and male genital organs: IARC press; 2004.
Cancer Statistics, 2017/ Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal.// CA CANCER J CLIN 2017; 67:7–30.
Silverman S.G. Management of the incidental renal mass / S.G. Silverman, G.M. Israel, B.R. Herts [et al.] // Radiology 2008; 249(1):16–31.
Curry N.S. Cystic renal masses: accurate Bosniak classification requires adequate renal CT / N.S. Curry, S.T. Cochran, N.K. Bissada // AJR Am J Roentgenol 2000;175(2):339–42.
Israel G.M. How I do it: evaluating renal masses / G.M. Israel, M.A. Bosniak // Radiology 2005; 236(2): 441–50.
Israel G.M. MR imaging of cysticrenal masses / G.M. Israel, M.A. Bosniak // Magn Reson Imaging Clin N Am 2004;12(3):403–12.
Tiwari P. Upper gastro intestinal bleeding – rare presentation of renal cell carcinoma./ P. Tiwari, A. Tiwari, M. Vijay, S. Kumar, A.K. Kundu // Urology Annals. 2010;2:127–129.
Edenberg J. The role of contrast enhanced ultrasound in the classification of CT indeterminate renal lesions / J. Edenberg, K. Gløersen, H.A. Osman, M. Dimmen, G.V. Berg // Scand J Urol. 2016 Dec;50(6):445-451. Epub 2016 Sep 9.
Chen Y. Comparison of contrast enhanced sonography with MRI in the diagnosis of complex cystic renal masses / Y. Chen, N. Wu, T. Xue, Y. Hao, J. Dai // J. Clin. Ultrasound 2014 Sep 1; Vol. 43, No 4. – Р. 203–209.
Renal Tumor Biopsy for Small Renal Masses: A Single center 13 year Experience / P.O. Richard [et al.] //Eur Urol, 2015. 68: 1007.
Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience/ A. Volpe [et al.]//J Urol, 2008. 180: 2333.
Systematic Review and Metaanalysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy / L.Marconi [et al.]//Eur Urol, 2016. 69: 660
Сергеева Н.С. Общие представления о серологических биомаркерах и их месте в онкологии/ Н.С. Сергеева, Н.В. Маршутина// Практическая онкология Т. 12, No 4. – 2011.
Kidney Cancer: Principles and Practice/ Primo N. Lara Jr., Eric Jonasch //Springer Verlag Berlin Heidelberg 2012.
Skates S. Molecular markers for early detection of renal carcinoma: investigative approach/ S. Skates, O. Iliopoulos // Clin Cancer Res.2004;10(18 Pt 2):6296S–301S.
Gupta V, Bamezai RN. Human pyruvate kinase M2: a multifunctional protein/ V. Gupta, R.N. Bamezai // Protein Sci. 2010;19(11):2031–44.
Roigas J. Tumor M2 pyruvate kinase in plasma of patients with urological tumors/ J. Roigas, G. Schulze, S. Raytarowski [et al.] //Tumour Biol. 2001;22(5):282–5.
Weinberger R. The pyruvate kinase isoenzyme M2 (Tu M2 PK) as a tumour marker for renal cell carcinoma/ R. Weinberger, B. Appel, A. Stein [et al.] // Eur J Cancer Care. 2007;16(4): 333–7.
Nisman B. Circulating Tumor M2 Pyruvate Kinase and Thymidine Kinase 1 Are Potential Predictors for Disease Recurrence in Renal Cell Carcinoma After Nephrectomy/ B. Nisman, V. Yutkin, H. Nechushtan [et al.] // UROLOGY 76: 513.e1–513.e6, 2010.
Wechsel H.W. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2 PK)/ H.W. Wechsel, E. Petri, K.H. Bichler, G. Feil//Anticancer Res. 1999; 19(4A): 2583–90.
Rioux Leclercq N. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases/ N. Rioux Leclercq, P. Fergelot, S. Zerrouki [et al.]//Hum Pathol. 2007;38(10):1489–95
Werther K. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets/ K. Werther, I.J. Christensen, H.J. Nielsen //Scand J Clin Lab Invest. 2002; 62(5):343–50.
Patruno R. VEGF concentration from plasma activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model/ R. Patruno, N. Arpaia, C.D. Gadaleta [et al.] // J. Cell. Mol. Med. Vol. 13, No 3, 2009 pp. 555–561.
Schetter A.J. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma / A.J. Schetter, S.Y. Leung, J.J. Sohn [et al.]// Jama. 2008; 299: 425–436.
Yanaihara N. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis/ N. Yanaihara, N. Caplen, E. Bowman [et al.] //Cancer Cell. 2006;9:189–198.
Iorio M.V. MicroRNA gene expression deregulation in human breast cancer/ M.V. Iorio, M. Ferracin, C.G. Liu [et al.] //Cancer Res. 2005; 65: 7065–7070.
Iorio M.V. MicroRNA signatures in human ovarian cancer/ M.V. Iorio, R. Visone, G. Di Leva [et al.] //Cancer Res. 2007;67:8699–8707.
Gu L. MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and metaanalysis / Gu L, Li H, Chen L. [et al.] //Oncotarget. 2015; 6(32): 32545 – 32560.
Bui M.H. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy/ M.H. Bui, D. Seligson, K.R. Han [et al.]//Clin Cancer Res. 2003 Feb; 9(2): 802–11.
Chamie K. Carbonic anhydrase IX score is a novel biomarker that predicts recurrence and survival for high risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial/ K. Chamie, P. Klöpfer, P. Bevan [et al.] //Urologic Oncology: Seminars and Original Investigations 33 (2015) 204.e25–204.e33
Eklund L. Angiopoietin signaling in the vasculature/ L. Eklund, P. Saharinen //Exp Cell Res. 2013; 319: 1271–1280.
Milam K.E. The angiopoietin Tie2 signaling axis in the vascular leakage of systemic inflammation/ K.E. Milam, S.M. Parikh //Tissue Barriers. 2015.
Fagiani E. Angiopoietins in angiogenesis/ E.Fagiani, G.Christofori // Cancer Lett. 2013; 328: 18–26.
Gerald D. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy/ D. Gerald, S. Chintharlapalli, H.G. Augustin, L.E. Benjamin // Cancer Res. 2013; 73: 1649–1657.
Wang X. The role of angiopoietins as potential therapeutic targets in renal cell carcinoma/ X. Wang, A.J. Bullock, L. Zhang [et al.]// Transl Oncol. 2014; 7: 188–195.
Gayed B.A. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma/B.A. Gayed, J. Gillen, A. Christie [et al.]// BMC Urol. 2015 Apr 3;15:24.
Григоренко В.М. Діагностичне значення молекулярних маркерів у хворих на нирково клітинний рак/ В.М. Григоренко, Г.В. Панасенко, Н.О. Сайдакова [et al.] Здоровье мужчины No 1 (56). 2016.
Fleischhacker M. Circulating nucleic acids (CNAs) and cancer a survey/ M. Fleischhacker, B. Schmidt //Biochim. Biophys. Acta 2007 (1775) 181–232.
Schwarzenbach H. Cell free nucleic acids as biomarkers in cancer patients/ H. Schwarzenbach, D.S. Hoon, K. Pantel// Nat. Rev. Cancer 11 (2011) 426–437.
Giacona M.B. Cellfree DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls/ M.B. Giacona, G.C. Ruben, K.A. Iczkowski, T.B. Roos, D.M. Porter, G.D. Sorenson //Pancreas 17 (1998) 89–97.
Jahr S. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells/ S. Jahr, H. Hentze, S. Englisch, D. Hardt, F.O. Fackelmayer, R.D. Hesch [et al.]// Cancer Res. 61 (2001) 1659–1665.
Wang B.G. Increased plasma DNA integrity in cancer patients/ B.G.Wang, H.Y. Huang, Y.C. Chen, R.E. Bristow, K. Kassauei, C.C. Cheng [et al.]// Cancer Res. 63 (2003) 3966–3968.
Schwarzenbach H. Cell free nucleic acids as biomarkers in cancer patients /H. Schwarzenbach, Dave S.B. Hoon and Klaus Pantel // Nature reviews cancer volume 11/June 2011.
